Ocugen Inc (OCGN)

$1.79 -0.02 (-1.10%)
Market Cap 593.49M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio 8.05
Volume 7,301,300
Avg Vol 8,228,890
Day's Range N/A - N/A
Shares Out 327.90M
Stochastic %K 11%
Beta 2.75
Analysts Strong Sell
Price Target $11.57

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
texmade2
texmade2 Apr. 2 at 1:52 AM
$SLS $GEVO $IBRX $OCGN Mysterious trader buys Ethereum As Trump is set to address the nation tonight, a mysterious trader purchased over $53 million worth of Ether hours earlier.
3 · Reply
texmade2
texmade2 Apr. 2 at 1:48 AM
$SLS $GEVO $IBRX $OCGN every time he opens his mouth.
2 · Reply
Cslater6879
Cslater6879 Apr. 2 at 12:37 AM
$OCGN The sentiment shifted for global economy is what happened. Don’t you have an X to harass or pud to pull or something?
0 · Reply
Tradefun1979
Tradefun1979 Apr. 2 at 12:27 AM
$OCGN
1 · Reply
shinseiRomeo
shinseiRomeo Apr. 1 at 11:59 PM
$OCGN What happened to the extreme positive sentiment and over $2.50 for a week talk?
0 · Reply
poopoohead123
poopoohead123 Apr. 1 at 11:35 PM
$OCGN don’t be silly like this
1 · Reply
mrpauley
mrpauley Apr. 1 at 11:29 PM
$OCGN pure speculation, but mirroring the fall served me very well when I used to day trade ocgn (holding now). circled is 1.82 from back in '22 and we look to be finishing in that spot two days in a row.
2 · Reply
Jangalang
Jangalang Apr. 1 at 11:29 PM
$OCGN … 12 out of the last 13 days negative. I’m trying to be positive, but I’m afraid this slow bleed is gonna continue. It’s only pumps when they have ER coming out or some kind of PR coming out.
1 · Reply
Snow120
Snow120 Apr. 1 at 10:23 PM
$OCGN paid pumper
0 · Reply
CasaDePapel
CasaDePapel Apr. 1 at 10:16 PM
$OCGN looks like the discord group gave up on pumping!
0 · Reply
Latest News on OCGN
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Apr 1, 2026, 7:02 AM EDT - 16 hours ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

Mar 24, 2026, 5:54 PM EDT - 8 days ago

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

Mar 24, 2026, 10:40 AM EDT - 8 days ago

Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 24, 2026, 7:45 AM EDT - 8 days ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Mar 23, 2026, 7:02 AM EDT - 9 days ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

Mar 4, 2026, 1:32 PM EST - 4 weeks ago

Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 4 weeks ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 4 weeks ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 7 weeks ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 2 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Jan 21, 2026, 4:37 PM EST - 2 months ago

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 2 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Jan 15, 2026, 2:16 PM EST - 2 months ago

Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Jan 15, 2026, 1:15 PM EST - 2 months ago

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 2 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 2 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 2 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 2 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Jan 6, 2026, 12:20 AM EST - 3 months ago

Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 4 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 4 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:21 PM EST - 5 months ago

Ocugen, Inc. (OCGN) Q3 2025 Earnings Call Transcript

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 5 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 5 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen: A Retinal Disease Juggernaut In The Making

Sep 23, 2025, 11:11 AM EDT - 6 months ago

Ocugen: A Retinal Disease Juggernaut In The Making

Ocugen Shares Are Trading Higher Monday: What's Going On?

Sep 15, 2025, 4:29 PM EDT - 7 months ago

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 7 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 7 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 8 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 8 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 8 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 12:30 PM EDT - 8 months ago

Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 8 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 9 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 9 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 9 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 10 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen: Three Potential Gene-Therapy Filings By 2028

Jun 18, 2025, 4:00 PM EDT - 10 months ago

Ocugen: Three Potential Gene-Therapy Filings By 2028

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 10 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 10 months ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 10 months ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 11 months ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:02 AM EDT - 11 months ago

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 11 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 11 months ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 10:59 AM EST - 1 year ago

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

texmade2
texmade2 Apr. 2 at 1:52 AM
$SLS $GEVO $IBRX $OCGN Mysterious trader buys Ethereum As Trump is set to address the nation tonight, a mysterious trader purchased over $53 million worth of Ether hours earlier.
3 · Reply
texmade2
texmade2 Apr. 2 at 1:48 AM
$SLS $GEVO $IBRX $OCGN every time he opens his mouth.
2 · Reply
Cslater6879
Cslater6879 Apr. 2 at 12:37 AM
$OCGN The sentiment shifted for global economy is what happened. Don’t you have an X to harass or pud to pull or something?
0 · Reply
Tradefun1979
Tradefun1979 Apr. 2 at 12:27 AM
$OCGN
1 · Reply
shinseiRomeo
shinseiRomeo Apr. 1 at 11:59 PM
$OCGN What happened to the extreme positive sentiment and over $2.50 for a week talk?
0 · Reply
poopoohead123
poopoohead123 Apr. 1 at 11:35 PM
$OCGN don’t be silly like this
1 · Reply
mrpauley
mrpauley Apr. 1 at 11:29 PM
$OCGN pure speculation, but mirroring the fall served me very well when I used to day trade ocgn (holding now). circled is 1.82 from back in '22 and we look to be finishing in that spot two days in a row.
2 · Reply
Jangalang
Jangalang Apr. 1 at 11:29 PM
$OCGN … 12 out of the last 13 days negative. I’m trying to be positive, but I’m afraid this slow bleed is gonna continue. It’s only pumps when they have ER coming out or some kind of PR coming out.
1 · Reply
Snow120
Snow120 Apr. 1 at 10:23 PM
$OCGN paid pumper
0 · Reply
CasaDePapel
CasaDePapel Apr. 1 at 10:16 PM
$OCGN looks like the discord group gave up on pumping!
0 · Reply
SIRWINSALOT
SIRWINSALOT Apr. 1 at 9:42 PM
$OCGN I approve this message
2 · Reply
ChiefNC9
ChiefNC9 Apr. 1 at 9:39 PM
$OCGN
0 · Reply
Martinsucks
Martinsucks Apr. 1 at 9:11 PM
$OCGN day 1 of not complaining.
0 · Reply
Manuelitos
Manuelitos Apr. 1 at 8:59 PM
$OCGN
0 · Reply
Lights1980
Lights1980 Apr. 1 at 8:49 PM
$OCGN it’s all a game, but maybe they should announce that they are shutting down and this thing will go up a few dollars that day. The algorithms kill the stock market on the small bios. You have to be in it for the long haul. Can be frustrating but the way I look at it at it, we are up 130% on the year.
0 · Reply
Kuzo1981
Kuzo1981 Apr. 1 at 8:41 PM
$OCGN AnyTime!
0 · Reply
jrich60
jrich60 Apr. 1 at 8:30 PM
$OCGN When this stock runs it will go straight up. Chasing won't be an option. https://x.com/MoreFlax/status/2039307111847362929?s=20
0 · Reply
thegreenhammer
thegreenhammer Apr. 1 at 8:29 PM
$OCGN this is the number one reason I’m confident that we will moon ! 🌙 @SIRWINSALOT show us your seal of approval! @Djtrush you are my hero next stop 🌖🙌🏽💪🏽⏰💣⏰😎👇🏽
1 · Reply
Wienandforever
Wienandforever Apr. 1 at 8:22 PM
$OCGN Now they are suddenly saying 2028, even though they have been telling us for months that there will be filing three BLAs by 2027... they keep pushing back the dates with every new announcement. The management is becoming increasingly unreliable.
4 · Reply
Bedtimereminder
Bedtimereminder Apr. 1 at 8:12 PM
$OCGN People keep trading the noise… but look at the timeline: → Phase 2 data (anytime)→ Phase 3 start (mid-2026)→ Stargardt interim (Q3) That’s 3 major catalysts lined up. This isn’t hype — it’s a setup.$3+ is just the first stop if things land right.
1 · Reply
milk25
milk25 Apr. 1 at 8:12 PM
$OCGN probably sideways in few days or couple of weeks....its time to accumulate
1 · Reply
tt01
tt01 Apr. 1 at 8:10 PM
$OCGN why going down???
0 · Reply